Abstract
Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 19-22 |
| Number of pages | 4 |
| Journal | Cancer |
| Volume | 42 |
| Issue number | 1 |
| State | Published - Dec 1 1978 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report. / Schein, P. S.; Lavin, P. T.; Moertel, C. G.; Frytak, S.; Hahn, R. G.; O'Connell, M. J.; Reitemeier, R. J.; Rubin, J.; Schutt, A. J.; Weiland, L. H.; Kalser, M.; Barkin, Jamie S; Lessner, H.; Mann-Kaplan, R.; Redlhammer, D.; Silverman, M.; Troner, M.; Douglass, H. O.; Milliron, S.; Lokich, J.; Brooks, J.; Chaffe, J.; Like, A.; Zamcheck, N.; Ramming, K.; Bateman, J.; Spiro, H.; Livstone, E.; Knowlton, A.
In: Cancer, Vol. 42, No. 1, 01.12.1978, p. 19-22.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report
AU - Schein, P. S.
AU - Lavin, P. T.
AU - Moertel, C. G.
AU - Frytak, S.
AU - Hahn, R. G.
AU - O'Connell, M. J.
AU - Reitemeier, R. J.
AU - Rubin, J.
AU - Schutt, A. J.
AU - Weiland, L. H.
AU - Kalser, M.
AU - Barkin, Jamie S
AU - Lessner, H.
AU - Mann-Kaplan, R.
AU - Redlhammer, D.
AU - Silverman, M.
AU - Troner, M.
AU - Douglass, H. O.
AU - Milliron, S.
AU - Lokich, J.
AU - Brooks, J.
AU - Chaffe, J.
AU - Like, A.
AU - Zamcheck, N.
AU - Ramming, K.
AU - Bateman, J.
AU - Spiro, H.
AU - Livstone, E.
AU - Knowlton, A.
PY - 1978/12/1
Y1 - 1978/12/1
N2 - Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.
AB - Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.
UR - http://www.scopus.com/inward/record.url?scp=0018182894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018182894&partnerID=8YFLogxK
M3 - Article
C2 - 352505
AN - SCOPUS:0018182894
VL - 42
SP - 19
EP - 22
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 1
ER -